Nivolumab plus ipilimumab in advanced melanoma. (Q27852310)

From Wikidata

Revision as of 09:49, 24 July 2019 by ԱշբոտՏՆՂ (talk | contribs) (‎Updated Item: hy:description:2013 թվականի հունիսին հրատարակված գիտական հոդված, hyw:description:2013 թուականի Յունիսին հրատարակուած գիտական յօդուած)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Nivolumab plus ipilimumab in advanced melanoma.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

title

Nivolumab plus ipilimumab in advanced melanoma. (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

main subject

nivolumab

0 references

ipilimumab

0 references

melanoma

0 references

author name string

Jedd D Wolchok

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Harriet Kluger

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Margaret K Callahan

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Michael A Postow

series ordinal

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Naiyer A Rizvi

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Alexander M Lesokhin

series ordinal

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Neil H Segal

series ordinal

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Charlotte E Ariyan

series ordinal

8

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Ruth-Ann Gordon

series ordinal

9

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Kathleen Reed

series ordinal

10

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Matthew M Burke

series ordinal

11

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Anne Caldwell

series ordinal

12

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Stephanie A Kronenberg

series ordinal

13

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Blessing U Agunwamba

series ordinal

14

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Xiaoling Zhang

series ordinal

15

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Israel Lowy

series ordinal

16

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Hector David Inzunza

series ordinal

17

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

William Feely

series ordinal

18

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Christine E Horak

series ordinal

19

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Quan Hong

series ordinal

20

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Alan J Korman

series ordinal

21

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Jon M Wigginton

series ordinal

22

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Ashok Gupta

series ordinal

23

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

Mario Sznol

series ordinal

24

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

language of work or name

English

0 references

publication date

2 June 2013

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

published in

The New England Journal of Medicine

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

volume

369

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

issue

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

page(s)

122-133

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Hallmarks of Cancer: The Next Generation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

retrieved

2 June 2018

Identifiers

DOI

10.1056/NEJMOA1302369

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

OpenCitations bibliographic resource ID

733191

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

733191

PMC publication ID

5698004

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

PubMed publication ID

23724867

1 reference

stated in

Europe PubMed Central

PMC publication ID

5698004

retrieved

14 December 2017

 

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852310&oldid=984788440"